Abstract

Meniere’s disease is chronic progressive disease with unclear idiopathic etiologyand symptomatic improvements with treatment. Objectives: To analyze the efficacy of lowdose intratympanic injection of gentamicin for vertigo control in unilateral Meniere’s disease.Study Design: Quasi experimental study. Settings: Department of ENT, PIMS, NESCOM &IMDC Islamabad. Materials & Methods: Gentamicin was used intra tympanically in thismulticentre study of 75 patients over a period of 8.5 years between 1st January 2005 to 30th June2013 in definite Meniere’s disease according to the 1995 Document of American academy ofotolaryngology- Head and Neck Surgery (AAO-HNS).All these centers followed same criteriaand procedures. Single dose of 1 ml Gentamicin solution 40 mg/ml was instilled in the middleear through the grommet under microscope and followed up for 3 months and two years. Thestaging of disease (hearing thresholds) the degree of disability (frequency of attacks per month)and the functional level were assessed before and after treatment. Results: Among 75 patients,41 were female & 34 were males between age ranges of 25 to 70 years. Most of the patients inthe study had stage 2 (23/75) and stage 3 (41/75) Meniere’s disease. About 68(91%) patientswere having good control of vertigo at the end of two year of intratympanic gentamicin withoutany loss of hearing. Conclusion: A single Low dose intratympanic gentamicin is effective incontrolling vertigo in patients with Meniere’s disease with no further deterioration in hearing forat least two years follow up.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call